Zeberati is the brand name for tirzepatide, a medication for chronic weight management [1]. It is not currently available as a generic drug [2].
When could a generic version of Zepbound become available?
The patent exclusivity for tirzepatide, the active ingredient in Zepbound, is a key factor in determining when a generic version might be introduced. Patent expiration dates and the potential for patent litigation significantly influence market entry for generics [3].
Who manufactures Zepbound?
Zepbound is manufactured by Eli Lilly and Company [1].
How does Zepbound work?
Tirzepatide is a dual-acting GIP and GLP-1 receptor agonist. It works by mimicking the actions of hormones that regulate appetite and blood sugar, leading to reduced food intake and improved metabolic control [1].
What are the approved uses for Zepbound?
Zepbound is indicated for chronic weight management in adults with obesity or who are overweight and have at least one weight-related condition, such as hypertension, type 2 diabetes, or dyslipidemia [1].
What is the difference between Zepbound and Mounjaro?
Both Zepbound and Mounjaro contain the active ingredient tirzepatide [4]. Mounjaro is approved for improving glycemic control in adults with type 2 diabetes [4]. Zepbound is specifically approved for chronic weight management in adults who are obese or overweight with a weight-related comorbidity [1]. While they share the same active molecule, their approved indications differ [1][4].
What are the common side effects of Zepbound?
Common side effects of Zepbound include gastrointestinal issues such as nausea, vomiting, diarrhea, constipation, and abdominal pain [1]. These side effects are generally mild to moderate and tend to decrease over time [1].
Can Zepbound be used to treat diabetes?
While tirzepatide, the active ingredient in Zepbound, also exists as Mounjaro, which is approved for type 2 diabetes management, Zepbound itself is indicated solely for chronic weight management [1][4].
What are the risks associated with Zepbound?
Potential serious risks associated with Zepbound include pancreatitis, gallbladder problems, kidney problems, severe allergic reactions, and thyroid C-cell tumors [1]. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use Zepbound [1].
What is the cost of Zepbound?
The list price for Zepbound is approximately $1,059.87 for a 28-day supply [5]. Actual costs may vary depending on insurance coverage and pharmacy [5].
What are the clinical trial results for Zepbound?
Clinical trials showed that tirzepatide resulted in significant weight loss in adults with obesity or overweight and at least one weight-related comorbidity [1]. For example, in one trial, participants taking the highest dose of tirzepatide achieved an average weight loss of 22.5% [1].
Where can I find more information about Zepbound patents?
Information on Zepbound's patents and exclusivity can be found on resources like DrugPatentWatch.com [3].
Sources:
[1] https://www.zepbound.com/
[2] https://www.goodrx.com/blog/what-is-zepbound-weight-loss-drug
[3] https://drugpatentwatch.com/
[4] https://www.mounjaro.com/
[5] https://www.zepbound.com/hcp/cost-and-savings